Replimune Group Stock Drops More Than 75% on News of FDA Complete Response Letter - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors - REPL

July 22, 2025 9:15 AM EDT | Source: Kehoe Law Firm, P.C.

Philadelphia, Pennsylvania--(Newsfile Corp. - July 22, 2025) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Replimune Group, Inc. ("Replimune") (NASDAQ: REPL).

On July 22, 2025, Replimune announced that the FDA ". . . issued a Complete Response Letter (CRL) regarding the Biologics License Application . . . for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma."

The FDA's CRL, according to Replimune, ". . . indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness."

On this news, shares of Replimune stock were down more than 76% pre-market on July 22, 2025.

Replimune investors who have incurred financial losses are encouraged to complete Kehoe Law Firm's Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the securities investigation and potential legal claims.

Additional information is available at https://kehoelawfirm.com/replimune-group-repl/.

ABOUT KEHOE LAW FIRM, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

This press release may constitute attorney advertising.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259616

info